CANF
Can-Fite BioPharma
CANF
CANF
8 hedge funds and large institutions have $1.5M invested in Can-Fite BioPharma in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$70K |
| 2 |
VF
2
Virtu Financial
New York
|
$19K |
| 3 |
3
UBS Group
Zurich,
Switzerland
|
$2K |
| 4 |
PCM
4
Prelude Capital Management
New York
|
$2K |
Top Sellers
| 1 |
PVH
1
Psagot Value Holdings
Tel Aviv,
Israel
|
$23K |
| 2 |
2
Citadel Advisors
Miami,
Florida
|
$20K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.35M | 796,500 | – | – |
|
|
2
Morgan Stanley
New York
| $70K | 41,600 | +29,300 | +238% |
|
|
PVH
3
Psagot Value Holdings
Tel Aviv,
Israel
| $23K | 13,891 | -20,235 | -59% |
|
|
RJA
4
Raymond James & Associates
St Petersburg,
Florida
| $21K | 12,200 | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $20K | 11,657 | -5,081 | -30% |
|
|
VF
6
Virtu Financial
New York
| $19K | 11,169 | +11,169 | New |
|
|
PCM
7
Prelude Capital Management
New York
| $2K | 1,200 | +400 | +50% |
|
|
8
UBS Group
Zurich,
Switzerland
| $2K | 1,314 | +1,314 | New |
|